Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection

PHASE2TerminatedINTERVENTIONAL
Enrollment

307

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

April 30, 2010

Study Completion Date

July 31, 2010

Conditions
HCV Infection
Interventions
DRUG

GS-9450

Taken as one capsule by mouth once daily

DRUG

Placebo

Taken as one placebo capsule (matching in appearance to GS-9450 capsules) by mouth once daily

Trial Locations (73)

Unknown

Phoenix

Tucson

Anaheim

Beverly Hills

Cypress

La Jolla

Mission Hills

Palm Springs

Pasadena

San Clemente

San Diego

Washington D.C.

Hialeah

Miami

North Miami Beach

Orlando

Sarasota

Tampa

Decatur

Chicago

Indianapolis

Louisville

Baton Rouge

New Orleans

Annapolis

Baltimore

Boston

Novi

Saint Louis

Plymouth

Omaha

Las Vegas

Hillsborough

Morristown

Santa Fe

Johnson City

New York

Plainview

Cincinnati

Cleveland

Philadelphia

Providence

Chattanooga

Germantown

Dallas

San Antonio

Fairfax

Falls Church

Norfolk

Seattle

Madison

Vancouver

Winnipeg

London

Berlin

Bonn

Cologne

Essen

Frankfurt am Main

Hamburg

Hanover

Mainz

Bialystok

Bydgoszcz

Chorzów

Kielce

Wroclaw

San Juan

Santurce

Brighton

London

Nottingham

Sheffield

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY